肯定是因为现在的试验比较少，包括倍力腾的试验并不多，主要是那几个试验大

It must be because there are relatively few trials now, and there are not many trials including Britton. The main reason is that we have repeatedly studied those few trials, but in fact, the population and new conditions we enter into the group for each trial are very limited. , Including the Belliteng test, you can see that the test data in it are all young patients, the average age is less than 30 years old, so of course, lupus patients themselves are more young patients, so this kind of patients has relatively serious adverse reactions It is relatively small, so can we open up more people based on evidence, and select more types. Of course, there are small ones now, not randomized controlled, but self-controlled before and after treatment. If the treatment fails, it will be relieved after the use of Britton of. It is these that I think if there are enough cases, we are also worth learning.

肯定是因为现在的试验比较少，包括倍力腾的试验并不多，主要是那几个试验大家反复学，但实际上我们做每个试验入组的人群和新的条件都是非常有限的，包括倍力腾试验，你可以看它里面的试验数据都是年轻病人，平均年龄30岁不到，所以说当然狼疮病人本身也是年轻病人比较多，所以说这种病人出严重不良反应的相对比较少，所以能不能在循证上开拓更多的人群，入选种类更多的，当然现在有小的，不是随机对照的，只是自身前后对照的，治疗失败的，再用倍力腾以后缓解的。是这些我觉得如果例数足够多，我们也值得借鉴。

It must be because there are few trials now, and there are not many trials including biliten. The main reason is that we have repeated the tests. But in fact, the population and new conditions for each trial are very limited. You can see that the data in the test are all young patients, with an average age of less than 30 years old. Therefore, of course, lupus patients are themselves There are more young patients, so there are relatively few patients with serious adverse reactions. Therefore, can we expand more groups of people and select more kinds of patients on the evidence-based basis. Of course, there are small ones, which are not randomized controlled, but are self controlled before and after treatment, and those who fail in treatment can be relieved after using biliten. I think that if there are enough cases, we should learn from them.<br>